UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P945: REAL‐WORLD CLINICAL OUTCOMES AMONG TRIPLE‐CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e642555a-n/a

2023

Volltextzugriff (PDF)

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Journal of clinical oncology, 2017-10, Vol.35 (29), p.3279-3289

2017

Volltextzugriff (PDF)

P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP

HemaSphere, 2023-08, Vol.7 (S3), p.e32107b7-n/a

2023

Volltextzugriff (PDF)

The Anti-CD38 Antibody Therapy in Multiple Myeloma

Cells (Basel, Switzerland), 2019-12, Vol.8 (12), p.1629

2019

Volltextzugriff (PDF)

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

The lancet oncology, 2015-12, Vol.16 (16), p.1617-1629

2015

Volltextzugriff (PDF)

Introduction to “Immunotherapies for Multiple Myeloma”

Pharmaceuticals (Basel, Switzerland), 2020-11, Vol.13 (11), p.396

2020

Volltextzugriff (PDF)

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells

The Journal of immunology (1950), 2015-07, Vol.195 (2), p.736-748

2015

Volltextzugriff (PDF)

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

Global & regional health technology assessment (Online), 2021-07, Vol.8, p.80-86

2021

Volltextzugriff (PDF)

Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment

Cancer research (Chicago, Ill.), 2015-11, Vol.75 (22), p.4766-4777

2015

Volltextzugriff (PDF)

Proteasome inhibitors for the treatment of multiple myeloma

Expert opinion on pharmacotherapy, 2018-03, Vol.19 (4), p.375-386

2018

Volltextzugriff (PDF)

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel

Haematologica (Roma), 2022-11, Vol.107 (11), p.2536-2547

2022

Volltextzugriff (PDF)

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Journal of clinical oncology, 2014-03, Vol.32 (7), p.634-640

2014

Volltextzugriff (PDF)

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Haematologica (Roma), 2018-09, Vol.103 (9), p.1422-1432

2018

Volltextzugriff (PDF)

Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1

The Journal of immunology (1950), 2014-07, Vol.193 (2), p.950-960

2014

Volltextzugriff (PDF)

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay

Journal of hematology and oncology, 2016-12, Vol.9 (1), p.134-134, Article 134

2016

Volltextzugriff (PDF)

Phytochemical Analysis and In Vitro Antileukemic Activity of Alkaloid-Enriched Extracts from Vinca sardoa (Stearn) Pignatti

Molecules (Basel, Switzerland), 2023-07, Vol.28 (15), p.5639

2023

Volltextzugriff (PDF)

Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis

Oncoimmunology, 2017-03, Vol.6 (3), p.e1279372-e1279372

2017

Volltextzugriff (PDF)

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment

Biomolecules (Basel, Switzerland), 2022-08, Vol.12 (8), p.1146

2022

Volltextzugriff (PDF)

A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

Mediterranean journal of hematology and infectious diseases, 2023-01, Vol.15 (1), p.e2023012

2023

Volltextzugriff (PDF)

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma

Oncotarget, 2015-09, Vol.6 (27), p.23609-23630

2015

Volltextzugriff (PDF)

1 – 25 von 457

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(436)
Mit Volltextzugriff
(417)

Publikationsform

Artikel
(453)
Berichte
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(208)
Life Sciences & Biomedicine
(203)
Humans
(168)
Female
(104)
Hematology
(101)
Male
(95)
Middle Aged
(93)
Aged
(90)
Multiple Myeloma
(83)
Oncology
(79)
Multiple Myeloma - Drug Therapy
(64)
Adult
(60)
Biological And Medical Sciences
(49)
Medical Sciences
(48)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(45)
Treatment Outcome
(38)
Multiple Myeloma - Mortality
(35)
Aged, 80 And Over
(30)
Melphalan - Administration & Dosage
(30)
Multiple Myeloma - Pathology
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

P945: REAL‐WORLD CLINICAL OUTCOMES AMONG TRIPLE‐CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP

The Anti-CD38 Antibody Therapy in Multiple Myeloma

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Introduction to “Immunotherapies for Multiple Myeloma”

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment

Proteasome inhibitors for the treatment of multiple myeloma

Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay

Phytochemical Analysis and In Vitro Antileukemic Activity of Alkaloid-Enriched Extracts from Vinca sardoa (Stearn) Pignatti

Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment

A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma

Suchergebnisse filtern